Canopy Growth (CGC) Price & Analysis
CGC Stock Chart & Stats
- Day’s Range
- $0.64 - $0.69
- 52-Week Range
- $0.64 - $2.38
- Previous Close
- $0.68
- Volume
- 1.63M
- Average Volume (3M)
- 2.42M
- Market Cap
- $296.70M
- Enterprise Value
- $518.37M
- Total Cash (Recent Filing)
- $336.63M
- Total Debt (Recent Filing)
- $277.33M
- Price to Earnings (P/E)
- ―
- Beta
- 1.41
- Next Earnings
- Nov 06, 2026
- EPS Estimate
- -0.03
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue And Margin Expansion
Broad-based revenue growth alongside a substantial margin improvement indicates that operating initiatives are translating into better economics. If sustained, higher gross margin can support reinvestment, reduce dependence on external funding, and improve the path toward durable profitability.
Improving Canadian Market Position
Gaining Canadian adult-use share while growing revenue suggests stronger brand execution in a competitive regulated market. Leadership in premium flower, infused pre-rolls, and softgels can support product mix, customer retention, and more resilient revenue over the next several quarters.
EU-GMP Certification
EU-GMP certification expands the facility’s ability to support regulated European medical cannabis channels and strengthens Canopy’s compliance credentials. This can improve access to international markets, support future shipments, and make the company’s production platform more strategically useful.
Bears Say
Persistent Unprofitability
Despite the recent operating improvement, Canopy remains deeply unprofitable and its multi-year earnings record is volatile. Continued losses weaken internal capital formation, increase execution pressure, and mean that revenue growth has not yet translated into a dependable earnings model.
Ongoing Cash Burn
Negative operating and free cash flow show that the business is still consuming cash rather than funding its operations internally. Until profitability improves, ongoing cash usage can constrain investment choices and increase reliance on available balance-sheet resources or financing.
Medical Reimbursement Pressure
The reimbursement reduction directly lowers order values in an important medical channel and creates a structural margin headwind. Canopy’s mitigation efforts may help, but sustained pricing pressure could limit medical growth economics and offset gains from patient and revenue expansion.
Canopy Growth News
CGC FAQ
What was Canopy Growth’s price range in the past 12 months?
What is Canopy Growth’s market cap?
When is Canopy Growth’s upcoming earnings report date?
How were Canopy Growth’s earnings last quarter?
Is Canopy Growth overvalued?
Does Canopy Growth pay dividends?
What is Canopy Growth’s EPS estimate?
How many shares outstanding does Canopy Growth have?
What happened to Canopy Growth’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Canopy Growth?
What is the TipRanks Smart Score and how is it calculated?
Canopy Growth Stock Smart Score
Company Description
Canopy Growth
Canopy Growth Corporation, through its various operating units, is actively involved in the cultivation, marketing, and distribution of cannabis and hemp-derived products. These offerings serve both recreational consumers and medical patients across key markets including Canada, the United States, and Germany. The company's business activities are structured into two main divisions: its global cannabis operations and its diverse portfolio of other consumer goods. Its extensive product line features dried cannabis flower, a variety of extracts and concentrates, beverages, edible gummies, and vaporization products. Canopy Growth commercializes these goods under numerous well-known brands such as Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra. Formed in 2009, the enterprise initially operated as Tweed Marijuana Inc. before adopting its current name, Canopy Growth Corporation, in September 2015. Its principal office is located in Smiths Falls, Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Luc Mongeau
- Employees
- 1,128
- Website
- www.canopygrowth.com
- Address
- 1 Hershey Drive, Smiths Falls, ON, K7A 0A8, CA
Canopy Growth (CGC) Earnings & Revenues
CGC Earnings Call
Earnings Call SentimentPositive
The call conveyed broad-based operational improvement and tangible progress: year-over-year revenue growth (+13% consolidated), strong segment performances (Canada medical +22%, cannabis +14%, Storz & Bickel +6%), substantial adjusted gross margin expansion (+600 bps to 31%), improved adjusted EBITDA (59% improvement), and a strong cash position (CAD 337M). Management outlined clear operational initiatives (cultivation yield, EU GMP certification, supply chain optimization) and reported meaningful synergies from the MTL acquisition (CAD 8M realized toward a CAD 10M target). Key challenges include a 29% Veterans Affairs reimbursement cut affecting medical margins, a CAD 2.6M non-cash acquisition-related charge lowering reported gross margin to 22%, continued negative adjusted EBITDA (albeit improved), and higher operating cash usage in the quarter. Overall, positives — consistent growth, margin improvement, and balance sheet strength — materially outweigh the remaining execution and market headwinds.
View all CGC earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 4 | 14 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 0 | 0 | 12 |